Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Inner Mongolia Eppen Biotech Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed across 2 distinct examiners, which means that each pending matter is being reviewed by a different official. Furthermore, the portfolio is spread across 2 distinct art units, which indicates that the company's current filings touch upon different specialized sub-sectors within the broader biotechnology field.
HAUK TEODORO, PRICILA NMN is the busiest examiner for this portfolio, currently handling 1 busiest examiner pending office action. This accounts for 1 of the 2 total pending office actions for the company. The distribution of 2 pending office actions across 2 distinct art units suggests a diversified approach to its intellectual property filings. Practitioners can expect to navigate different examiner preferences and art unit standards as they manage these separate pending matters. With 2 distinct examiners involved, the company must maintain multiple lines of communication to resolve its 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, ASHLEY TAYLOR | 1 | 25.0% | +46.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270490 | RECOMBINANT STRAIN WITH MODIFIED GENE BBD29_04920 FOR PRODUCING L-GLUTAMIC ACID, AND METHOD FOR CONSTRUCTING THE SAME AND USE THEREOF | WHITE, ASHLEY TAYLOR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270490 | RECOMBINANT STRAIN WITH MODIFIED GENE BBD29_04920 FOR PRODUCING L-GLUTAMIC ACID, AND METHOD FOR CONSTRUCTING THE SAME AND USE THEREOF | WHITE, ASHLEY TAYLOR | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270490 | RECOMBINANT STRAIN WITH MODIFIED GENE BBD29_04920 FOR PRODUCING L-GLUTAMIC ACID, AND METHOD FOR CONSTRUCTING THE SAME AND USE THEREOF | WHITE, ASHLEY TAYLOR | 1653 | §103 | Non-Final OA | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial